Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial
Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial
复制标题
DOI：
10.1128/iai.73.1.369-377.2005
复制
发表时间：
2005-01-01
影响因子：
3.1
通讯作者：
Käyhty, H
中科院分区：
文献类型：
--
作者：
Ekström, N;Åhman, H;Käyhty, H
新的肺炎球菌结合疫苗（PCVs）的许可依赖于免疫原性数据。在确定保护相关因素时，必须包括疫苗效力数据。在FinOM疫苗功效试验中，PncOMPC疫苗显示出与许可的PncOMPC疫苗相似的功效，尽管初次接种和加强接种后的抗体反应不同。我们在参加FinOM试验的婴儿亚组中测定了抗体动力学和活力。共有166名婴儿在2、49、6和12月龄时接种了7价PCV、PncCRM或PncOMPC或乙肝疫苗。在2、4、6、79、12、13和24月龄时测定血清免疫球蛋白G （IgG）对肺炎球菌荚膜多糖的浓度，在7、12、13和24月龄时测定血清6B、19F和23F的亲和力指数（AI）。两种pcv均具有高度的免疫原性，但表现出不同的抗体反应动力学；第3、4次疫苗接种后，PncOMPC组6B、19F、23F血清型IgG浓度下降速度快于PncOMPC组。对于这两种pcv，在随访期间，抗- 6b和-23F的平均AI增加，而抗- 19f的平均AI没有增加，这与FinOM试验中的血清型特异性保护一致。我们的数据表明，在确定保护相关因素时，除了抗体反应外，还应考虑抗体的动力学和活性。
The licensure of new pneumococcal conjugate vaccines (PCVs) relies on immunogenicity data. When defining correlates of protection, vaccine efficacy data must be included. In the FinOM Vaccine Efficacy Trial, the PncOMPC vaccine showed an efficacy profile similar to that of the licensed PncCRM vaccine despite different antibody responses after primary and booster vaccinations. We determined antibody kinetics and avidities in a subgroup of infants participating in the FinOM trial. A total of 166 infants in three vaccine groups were immunized at 2, 49 6, and 12 months of age with 7-valent PCV, PncCRM or PncOMPC, or hepatitis B vaccine. Concentrations of serum immunoglobulin G (IgG) against pneumococcal capsular polysaccharides were determined at 2, 4, 6, 79 12, 13, and 24 months of age, and the avidity index (AI) to serotypes 6B, 19F, and 23F were determined at 7, 12, 13, and 24 months of age by enzyme immunoassay. Both PCVs were highly immunogenic, but they demonstrated different kinetics of antibody response; the concentration of IgG against serotypes 6B, 19F, and 23F declined faster after the third and fourth doses of vaccine in the PncCRM group than in the PncOMPC group. For both PCVs, the mean AI of anti-6B and -23F, but not of anti-19F, increased during the follow-up, which is in line with serotype-specific protection in the FinOM trial. Our data suggest that the kinetics and avidities of antibodies should be considered, in addition to antibody responses, when defining correlates of protection.